{"organizations": [], "uuid": "c557e15bbb247bb155e710c4a0ed7fce12c44158", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s1.reutersmedia.net/resources/r/?m=02&d=20180501&t=2&i=1257309148&w=1200&r=LYNXMPEE40232", "site_section": "http://feeds.reuters.com/reuters/INbusinessNews", "section_title": "Reuters: Money News", "url": "https://in.reuters.com/article/merck-co-results/keytruda-powers-merck-to-first-quarter-beat-idINKBN1I23GL", "country": "US", "domain_rank": 408, "title": "Keytruda powers Merck to first-quarter beat", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T14:16:00.000+03:00", "replies_count": 0, "uuid": "c557e15bbb247bb155e710c4a0ed7fce12c44158"}, "author": "", "url": "https://in.reuters.com/article/merck-co-results/keytruda-powers-merck-to-first-quarter-beat-idINKBN1I23GL", "ord_in_thread": 0, "title": "Keytruda powers Merck to first-quarter beat", "locations": [], "entities": {"persons": [{"name": "keytruda", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "cardiff", "sentiment": "none"}, {"name": "januvia", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "reuters) - drugmaker merck & co", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Drugmaker Merck & Co reported a better-than-expected first-quarter profit on Tuesday and raised its adjusted earnings forecast for the year, helped by a more than 150 percent rise in sales of cancer drug Keytruda.\nFILE PHOTO: The logo of Merck is pictured in this illustration photograph in Cardiff, California, U.S., April 26, 2016. REUTERS/Mike Blake/File Photo Keytruda, which replaced diabetes treatment Januvia as Merckâ€™s biggest drug by revenue last year, raked in sales of $1.46 billion in the quarter, ahead of the estimated $1.40 billion, according to Thomson Reuters I/B/E/S.\nThe company raised its adjusted per-share earnings forecast for the year to between $4.16 and $4.28 from between $4.08 and $4.23 estimated previously.\nNet income fell to $736 million, or 27 cents per share, from $1.55 billion, or 56 cents per share, a year earlier.\nExcluding items, the company earned $1.05 per share. Revenue rose 6.4 percent to $10.04 billion.\nAnalysts on average were expecting earnings of $1 per share on revenue of $10.11 billion.\nReporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva\n ", "external_links": [], "published": "2018-05-01T14:16:00.000+03:00", "crawled": "2018-05-01T14:48:21.018+03:00", "highlightTitle": ""}